PLUS THERAPEUTICS, INC. (PSTV): Nasdaq/NYSE listing notice — Plus Therapeutics receives Nasdaq extension to May 22, 2023 to regain minimum bid price compliance

PLUS THERAPEUTICS, INC.

Received second letter from Nasdaq granting 180-day extension to May 22, 2023 to regain minimum bid price compliance.
Previously notified on May 24, 2022 of bid price below $1.00; original compliance period ended Nov 21, 2022.
Company will evaluate options including a reverse stock split, if approved by stockholders.
Failure to regain compliance by May 22, 2023 may result in delisting; rights to appeal exist.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

PLUS THERAPEUTICS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

November 22, 2022, the Company received a second letter from Nasdaq advising that the Company had been granted an additional 180 calendar days, or to May 22, 2023, to regain compliance with the Minimum Bid Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Company intends to continue to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Requirement. Specifically, the Company has confirmed to Nasdaq that, if necessary, it will implement a reverse stock split of its outstanding common stock

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-293409

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.